Type 2 Diabetes Remission in Young Adults: Diet + Exercise

In a randomized clinical trial of adults aged 18 to 45 with early-onset type 2 diabetes and obesity, 54% of those who followed a 24-week intensive program of low-calorie diet plus supervised exercise reached remission. In the usual-care group, the figure was about 4%. The results were presented at the EASD Annual Meeting and published in The Lancet Regional Health – Americas. They are promising, but the trial was small and short.

What happened

The study was led by Professor Kaberi Dasgupta (McGill University, Montreal) and Professor Thomas Yates (University of Leicester, UK), with colleagues. It was run at three centers in England and Canada (Leicester, McGill, and the University of Alberta). Researchers enrolled adults aged 18 to 45 with early-onset type 2 diabetes (EOT2D) and obesity who were not using insulin. Between September 2021 and June 2025, 96 participants were randomized: 50 to the intensive intervention and 46 to standard care. Mean age was 38 years and mean BMI was 35.2 kg/m².

The design was open-label, so participants and investigators knew who got which treatment. However, the assessment of the main outcome was blinded.

The intervention group followed a two-phase program:

• Weeks 1–12: 800–900 kcal/day (30% protein, 50% carbohydrate, 20% fat). All meals were replaced with formulated products for the first two weeks. From week 3, one conventional meal per day was allowed, with targets for protein, fruit, and non-starchy vegetables. Supervised aerobic and resistance exercise took place twice weekly, plus one independent session per week.
• Weeks 13–24: a weight-maintenance diet while continuing to exercise independently.

At the start of the program, glucose-lowering drugs were stopped under medical supervision. So were antihypertensives in participants without albuminuria.

Remission was defined as HbA1c below 6.5% (48 mmol/mol) at 24 weeks with no glucose-lowering medication for at least 12 weeks. Analysis included everyone randomized, and missing remission data were counted as "no remission."

Results at 24 weeks:

• Remission occurred in 27 of 50 intervention participants (54%) versus 2 of 46 controls (about 4%).
• After adjustment, the intervention group was 21 times more likely to reach remission.
• In participants with weight data, mean weight fell from 100.7 kg to 92.3 kg (−8.4 kg) with the intervention. In controls it fell from 103.2 kg to 102.0 kg (−1.2 kg).
• The adjusted between-group difference was 7.5 kg, including 6.6 kg of fat loss.
• No severe adverse events were reported. Still, at least one adverse event occurred in 43 of 50 intervention participants versus 6 of 46 controls. Most were early and included constipation, headache, dizziness, and fatigue, and they generally resolved.

Why it matters

Type 2 diabetes diagnosed at a younger age can be aggressive. As the source describes, people with EOT2D often lose glycemic control faster, develop complications earlier in life, and have shorter life expectancy than those diagnosed later. Younger patients are also underrepresented in many lifestyle trials, so a randomized study focused on under-45s fills a gap.

Earlier research has shown that very low-calorie diets can lower glucose enough for some people to come off diabetes medication. This trial asked whether adding structured exercise to the diet could improve on that. The investigators also looked at fitness, body composition, and heart structure. Exercise is expected to improve fitness, protect muscle during weight loss, support heart function, and reduce insulin resistance.

One key point: remission is not the same as cure. It means HbA1c stays below the diagnostic threshold without glucose-lowering drugs. The underlying predisposition may persist.

What to know for the USMLE: type 2 diabetes, insulin resistance, and weight loss

• Pathophysiology: type 2 diabetes combines peripheral insulin resistance (skeletal muscle, liver, adipose tissue) with progressive β-cell dysfunction. Early on, β-cells compensate with hyperinsulinemia. Over time, secretion fails to keep up.
• Obesity link: excess visceral and ectopic fat (including liver) promotes insulin resistance through free fatty acids and adipokines. Weight loss, especially fat loss, improves hepatic and peripheral insulin sensitivity. That is the rationale for diet-induced remission.
• Glucotoxicity and lipotoxicity: chronic hyperglycemia and elevated free fatty acids impair β-cell function. Lowering them can partly restore insulin secretion in early disease. Longer disease duration with more β-cell loss predicts a smaller chance of reversal.
• Exercise physiology: muscle contraction increases GLUT4 translocation through insulin-independent mechanisms (including AMPK activation). Training also improves insulin sensitivity.
• Diagnostic criteria (ADA): HbA1c ≥6.5%, fasting plasma glucose ≥126 mg/dL, 2-hour OGTT glucose ≥200 mg/dL, or random glucose ≥200 mg/dL with classic symptoms. Prediabetes corresponds to HbA1c 5.7–6.4%.
• HbA1c pitfalls: it reflects roughly 3 months of average glycemia. It can be unreliable with anemia, recent transfusion, hemolysis, or hemoglobinopathies.
• Medication context: stopping agents such as sulfonylureas (hypoglycemia risk) or SGLT2 inhibitors (risk of euglycemic DKA, especially with very low intake) during severe caloric restriction is a recurring clinical-reasoning theme. Metformin is the classic first-line drug for most patients.
• Albuminuria: it is an early marker of diabetic nephropathy. Its presence matters for the choice of antihypertensive (ACE inhibitor or ARB are typically used in diabetic kidney disease), which is why the protocol distinguished patients with and without it.
• Starvation physiology: a very low-calorie diet lowers insulin, increases lipolysis, and raises ketone production. Fatigue, dizziness, headache, and constipation are common early symptoms in this setting.
• Complications: microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (CAD, stroke, PAD). Earlier onset means more years of exposure.

Limitations

• Small sample: 96 participants across three centers is modest. Estimates, including the "21 times more likely" figure, carry uncertainty. The source does not give confidence intervals.
• Short follow-up: the primary outcome was assessed at 24 weeks. The source material does not report whether remission lasted beyond that point, and this is the central open question.
• Open-label design: participants and researchers knew group assignments. Only outcome assessment was blinded. The comparison was also an intensive supervised program versus usual care, not versus another active intervention.
• Heavy intervention: supervised exercise, formulated meal products, and medical oversight during medication withdrawal may be hard to reproduce outside a research setting.
• Population: adults aged 18–45 with obesity who were not on insulin. The results should not be assumed to apply to older patients, people using insulin, or those with a different body habitus.
• Missing data and tolerability: some weight data were missing (47 of 50 and 43 of 46 had weight data). Adverse events were frequent in the intervention group, although non-severe and mostly early.
• Presentation: the findings were presented at a conference and published in a journal. Replication in larger trials would strengthen them.

This article is educational and does not offer treatment advice for individuals.

FAQ

What does "remission" of type 2 diabetes mean in this study?

HbA1c below 6.5% (48 mmol/mol) at 24 weeks, with no glucose-lowering medication for at least 12 weeks. It does not mean the disease is permanently cured.

Does this trial prove diet and exercise reverse type 2 diabetes long term?

No. The outcome was measured at 24 weeks in 96 participants. The source does not report how long remission lasted, so long-term durability remains unanswered.

Is early-onset type 2 diabetes tested on the USMLE?

Early-onset type 2 diabetes is not a separate topic, but the underlying concepts are core. These include insulin resistance, β-cell failure, obesity, HbA1c criteria, complications, and the effects of lifestyle on glycemia.

Key takeaways

• In a 96-person randomized trial of adults under 45 with type 2 diabetes and obesity, 54% of the diet-plus-exercise group reached remission at 24 weeks versus about 4% with usual care.
• The intervention led to greater weight loss (about 7.5 kg more after adjustment, including 6.6 kg of fat). Adverse events were more frequent but not severe.
• The trial was small, open-label, and short, and the source gives no data on long-term remission. For the USMLE, tie the result to insulin resistance, β-cell dysfunction, HbA1c criteria, and the effects of weight loss and exercise.